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The Diego blood group system (DI) currently encompasses 22 
antigens. Three of the antigens are of high prevalence and the 
other 19 are of low prevalence. The antigens of the Diego blood 
group system are carried on the erythroid band 3 protein anion 
exchanger 1 (AE1), the product of a single gene, SLC4A1 (solute 
carrier family 4, anion exchanger, member 1). AE1 is a member 
of a family of three anion exchangers or transporters expressed 
in a variety of tissues. This protein is involved in carbon dioxide 
transport from tissues to lungs. It is also found in the kidney, 
where it is involved in acid secretion. Antibodies to Diego system 
antigens with the exception of anti-Dia, -Dib, -Wra, -ELO and 
-DISK do not seem to be of clinical significance for transfusion 
or of importance in hemolytic disease of the fetus and newborn. 
Immunohematology 2013;29:73–81.
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History
Currently there are a total of 22 antigens in the Diego blood 
group system. Three of the antigens are of high prevalence, Dib, 
Wrb, and DISK. The other 19 antigens are of low prevalence. 
Within the 22 antigens there are only three sets of antithetical 
antigens: Dia/Dib, Wra/Wrb, and Wu/DISK. None of the other 
17 low-prevalence antigens has an antithetical high-prevalence 
antigen yet described. Figure 1 illustrates the molecule that 
carries the Diego system antigens.
The discoveries of these antigens exemplify the tenacity 
and curiosity of many immunohematologists and researchers. 
These individuals investigated many serum samples and in 
some cases came out with more questions (findings) than 
answers. On many occasions the new antibody discovered was 
present in sera that were under investigation for some other 
reason and contained antibody(ies) to other low-prevalence 
antigens. In other instances the antibody was discovered 
because it caused hemolytic disease of the fetus and newborn 
(HDFN) or an incompatible crossmatch in the presence of a 
negative antibody detection test.
The first antigen assigned to the Diego system, Dia, was 
reported by Layrisse et al. in 1955. They reported an antibody 
to a low-prevalence antigen that caused a fatal HDFN.1
Diego Blood Group Antigens Carried on Band 3 
Protein
The antigens of the Diego blood group are carried on 
the erythroid band 3 protein anion exchanger 1 (AE1), the 
product of a single gene, SLC4A1 (solute carrier family 4, anion 
exchanger, member 1). The gene is located on chromosome 
17q21.31, and the cluster differentiation assignment is CD233. 
SLC4A1 consists of 20 exons that span more than 18 kbp of 
DNA.2
The erythroid band 3 protein is a member of a family 
of three anion exchangers or transporters—AE1, AE2, and 
AE3—and is expressed in a variety of tissues. AE1 is the 
major integral membrane protein of the erythrocyte. This 
protein is a chloride-bicarbonate exchanger involved in carbon 
dioxide transport from tissues to lungs. AE1 is expressed in 
erythrocytes and the kidney, with the kidney having a different 
isoform of the protein. AE1 is not expressed by nonerythroid 
blood cells.3
Fig. 1 Diagram of band 3 and the locations of the Diego system 
antigens. Reprinted from The Blood Group Antigen FactsBook, 3rd 
ed. Reid ME, Lomas-Francis C, Olsson ML. Diego Blood Group 


















































Carrier protein for the DI system antigens
Band 3 on intact RBCs is cleaved by a-chymotrypsin at residues 553 and 555 in the third 
extracellular loop.
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Mutations of the band 3 gene have been implicated in 
Southeast Asian ovalocytosis (SAO), hereditary spherocytosis, 
congenital acanthocytosis and distal tubular acidosis. Band 3 
SAO has the Memphis I variant and is not functional as anion 
transporter.4 Another variant is known as band 3 Memphis 
II. Spring et al. reported that the Dia antigen is carried on the 
Memphis II variant of band 3.5
It has been reported that naturally occurring antibodies to 
low-prevalence antigens in the Diego system are common in 
the plasma of patients with hyperactive immune systems, e.g., 
those with autoantibodies. This may be related to the exposure 
of the senescent cell antigen, which resides on protein residues 
in band 3.6
Band 3 and Glycophorin A
Band 3 and glycophorin A (GPA) are the two most abun-
dant integral proteins of the red blood cell (RBC) membrane 
(Figure 2). The extracellular domains of both proteins are 
highly polymorphic. Band 3 carries the antigens of the Diego 
blood group system, and GPA and glycophorin B (GPB) carry 
the antigens of the MNS system. There is evidence that band 3 
and GPA associate in the RBC membrane, and the Wrb antigen, 
although a product of the band 3 gene, requires a complex of 
GPA and band 3 for normal expression. The discovery of a 
novel GPA mutation (Ala84Pro) giving rise to aberrant Wrb 
expression provided some of the initial information with 
regard to the site of interaction of the two proteins.7
In contrast to GPA-related antigens (which are the result of 
events between two closely linked genes and different genetic 
mechanisms), the antigens on band 3 are exclusively caused 
by single-nucleotide polymorphisms (SNPs) in the band 3 
gene, SLC4A1.8 All low-prevalence  antigens in the DI system, 
with the exception of Bpa, occur from extracellular amino acid 
substitutions. Some amino acid residues have been associated 
with more than one substitution, each giving rise to separate 
antigens, for example NFLD/BOW, Jna/KREP, and Hga/
Moa. Table 1 lists the 22 phenotypes encoded by the alleles 
in the DI system and summarizes the alleles and amino acid 
substitutions.
Effect of Enzymes on the Diego System Antigens
The effect of enzymes on the Diego blood group 
antigens is directly related to their location. Band 3 has two 
α-chymotrypsin cleavage sites in the third extracellular loop, 
at Tyr553 and Tyr555. Therefore the antigens in the third loop 
are sensitive to α-chymotrypsin, and those in the fourth and 
Fig. 2 Schematic diagram of the erythrocyte membrane (lateral view) showing major membrane-spanning proteins. Source: Kodippili GC, 
et al. Blood 2009;113:6237–45.
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seventh loops are resistant. Data available for some of the DI 
system antigens indicate that they are resistant to the effects 
of dithiothreitol, sialidase, and acid. Refer to Table 2 for details 
on the effect of enzymes and other chemicals on the DI system 
antigens.
Antigens and Antibodies in the Diego System
Like most antigens, the low-prevalence antigens in the 
Diego system were discovered by first encountering the 
antibodies that define them. Most of the low-prevalence 
antigens in the Diego system, DI5 to DI21, are of very low 
prevalence. Some antigens have only been found in one 
family; therefore, information on their characteristics and 
clinical significance is very limited. It is important to mention 
that although the antigens are rare, the antibodies to them 
are very common. Table 3 summarizes the antibodies, their 
immunoglobulin types, and the limited information regarding 
their clinical significance.
Dia (DI1)
In 1955, Layrisse et al. reported an antibody to a low-
prevalence  antigen that caused a fatal HDFN.1 The Dia antigen 
is the result of a 2561C>T transition in exon 19, Pro854Leu, 
in the seventh ectoplasmic loop of band 3. The antibody was 
named Dia after the antibody producer, Mrs. Diego. Further 
family studies of the proposita and investigations using the 
maternal serum helped to unveil the interesting history of 
the Dia antigen and the genetic, anthropologic, and clinical 
relevance of the antigen.
The Dia antigen is characteristic of individuals of Mongoloid 
descent, and the DI*A alleles have never been found in 
individuals of unmixed European descent. The Dia antigen has 
been used as an anthropologic population migration marker. 
An example of this migration marker is the presence of the 
Dia antigen in Poles, which can be explained by the invasion 
of southern Poland by Tartars in the 13th to 17th centuries.9 
Gene frequency in eastern Asians has been reported as 1 to 
5 percent. In Korea and Tibet the frequency ranges from 7 to 
8 percent. In some South American Indian tribes, the gene 
frequency can be as high as 40 percent; it is nonexistent in 
others. In Central American Indians, the frequency can also be 
high. In North American Indians, the frequency ranges from 
2 to 12 percent in some tribes. The gene is absent in Eskimos.6
Anti-Dia is most often RBC stimulated and mostly 
immunoglobulin (Ig) G1 and IgG3. A few examples of 
Table 1. Diego blood group system phenotypes. NOTE: Reference allele DI*2 (DI*B) encodes Dib (DI2), DI4, and DI22.
Phenotype encoded by allele ISBT No. Allele name Nucleotide change Exon Amino acid change
Di(a+b−)/DI:1,–2 10.1 DI*01 2561C>T 19 Pro854Leu
Wr(a+b−)/DI:3,–4 10.3 DI*02.03 1972G>A 16 Glu658Lys
DI:5 or Wd(a+) 10.5 DI*02.05 1669G>A 14 Va1557Met
DI:6 or Rb(a+) 10.6 DI*02.06 1643C>T 14 Pro548Leu
DI:7 or WARR+ 10.7 DI*02.07 1654C>T 14 Thr552Ile
DI:8 or ELO+ 10.8 DI*02.08 1294C>T 12 Arg432Trp
Wu+, DISK− /DI:9,–22 10.9 DI*02.09 1694G>C 14 Gly565Ala
DI:10 or Bp(a+) 10.10 DI*02.10 1707C>A 14 Asn569Lys
DI:11 or Mo(a+) 10.11 DI*02.11 1967G>A 16 Arg656His
DI:12 or Hg(a+) 10.12 DI*02.12 1966G>T 16 Arg656Cys
DI:13 or Vg(a+) 10.13 DI*02.13 1663T>C 14 Tyr555His
DI:14 or Sw(a+) 1014 DI*02.14.01; DI*02.14.02 1937G>A; 1936C>T 16; 16 Arg646Gln; Arg646Trp
DI:15 or BOW+ 10.15 DI*02.15 1681C>T 14 Pro561Ser
DI:16 or NFLD+ 10.16 DI*02.16 1287A>T; 1681C>G 12; 14 Glu429Asp; Pro561Ala
DI:17 or Jn(a+) 10.17 DI*02.17 1696C>T 14 Pro566Ser
DI:18 or KREP+ 10.18 DI*02.18 1696C>G 14 Pro566Ala
DI:19 or Tr(a+) 10.19 DI*02.19 1653C>G 14 Lys551Asn
DI:20 or Fr(a+) 10.20 DI*02.20 1438G>A 13 Glu480Lys
DI:21 or SW1+ 10.21 DI*02.21 1936C>T 16 Arg646Trp
ISBT = International Society of Blood Transfusion.
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agglutinins with anti-Dia specificity have been reported in 
individuals with no known RBC exposure. A few examples of 
anti-Dia have been shown to activate complement, and they 
have demonstrated the capability of causing in vitro hemolysis 
as well as causing severe immediate or delayed transfusion 
reactions.10 As previously mentioned, anti-Dia has caused 
serious HDFN. It has been recommended that in populations 
at risk a Di(a+) RBC be added to the routine antibody detection 
cells.
Dib (DI2)
The Dib antigen differs from Dia by a single amino acid 
change, Leu854Pro, on band 3. The antigen is found in all 
populations. Dib is weakly expressed in individuals with SAO, 
and it has also been reported as weakened in several Mexican 
American individuals.
Anti-Dib was first reported by Thompson et al. in 
1967.11 The antibody may cause mild cases of HDFN, yield a 
positive direct antiglobulin test (DAT), or exhibit no clinical 
manifestation. Anti-Dib has caused moderate or delayed 
transfusion reactions. Anti-Dib may show dosage in serologic 
testing. A few examples of autoanti-Dib have been reported.12
Wra (DI3)
The Wra antigen was first reported by Holman in 1953 
and assigned to the DI system in 1995.13 Wra differs from the 
Wrb antigen by a single nucleotide change, 1972G>A, at exon 
16, producing the amino acid change Glu658Lys.
Anti-Wra is a relatively common antibody and has a wide 
range of reactivity. The antibody can be an IgM agglutinin 
reacting at temperatures below 37°C or an IgG agglutinin 
reacting only at the antiglobulin phase of testing (AGT). Anti-




papain Trypsin a-chymotrypsin Pronase Sialidase
DTT  
(200 mM) Acid
BOW R R S S PR R PR
Bpa S S S S PR PR PR
Dia R R R R R R R
Dib R R R R R R R
DISK R R S S PR R PR
ELO R R V V PR R PR
Fra R PR PR PR PR PR PR
Hga R R R R PR PR PR
Jna R R S PS PR R PS
KREP R R S PS PR R PR
Moa R R R R PR R PR
NFLD R R S S PR R PR
Rba V R V V PR PR PR
Swa R R R PR PR PR PR
SW1 R R R PR PR PR PR
Tra R R S PS PR PR PR
Vga R R S S PR PR PR
WARR R R S S PR R PR
Wda R R S PS PS R R
Wra R R R R R R R
Wrb R R R R R R R
Wu R R S S PR R PR
DTT = dithiothreitol; R = resistant; S = sensitive; PR = presumed resistant;  
V = variable; PS = presumed sensitive.
NOTE:  The effect of the listed chemicals on the DI antigens was collected 
from many of the references listed at the end of this review.
Table 3. Immunoglobulin type and clinical significance of Diego 
system antibodies
Antibody Immunoglobulin class HDFN HTR
BOW IgG, some IgM NI NI
Bpa IgM No NI
Dia IgG Mild–severe None–severe
Dib IgG Mild No–moderate
DISK IgM, IgG Possible Possible
ELO IgG Mild–severe NI
Fra IgG, IgM Pos DAT only NI
Hga IgM, IgG NI NI
Jna IgM NI NI
KREP IgM NI NI
Moa IgM, IgG NI NI
NFLD IgM, IgG NI NI
Rba IgM NI NI
Swa IgM, IgG NI NI
SW1 IgM, IgG NI NI
Tra IgM, IgG NI NI
Vga IgM NI NI
WARR IgG Mild NI
Wda IgM NI NI
Wra IgM, IgG Mild–severe None, severe, 
immediate, delayed
Wrb IgM, IgG NI NI
Wu IgM, few IgG NI NI
HDFN = hemolytic disease of the fetus and newborn; HTR = hemolytic 
transfusion reaction; DAT = direct antiglobulin test; Ig = immunoglobulin;  
NI = no information.
NOTE: The HDFN and HTR information presented was collected from many 
of the references listed at the end of this review.
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Wra has caused severe HDFN and hemolytic transfusion 
reactions (HTRs). It has been speculated that there may 
be some examples of anti-Wra that are benign, as routine 
antibody detection reagent RBCs do not contain the Wra 
antigen and HTR caused by anti-Wra has not been reported 
since the widespread use of immediate spin (IS) and electronic 
compatibility testing.14
Wrb (DI4)
The Wrb antigen was first described in 1971 by Adams 
et al., but not assigned to the DI system until 1995.15 The Wrb 
antigen expression is dependent on the presence of GPA and 
band 3.
Wrb is absent from En(a–) erythrocytes, which lack GPA. 
However, GPA from En(a+), Wr(b–) RBCs has an amino 
acid sequence identical to that of GPA from En(a+), Wr(b+) 
erythrocytes. Wrb requires the interaction of GPA with 
erythrocyte integral membrane protein, band 3.4,7,16
The Wr(b–) phenotype with normal GPA may be explained 
by the change from a negatively to a positively charged 
residue at position 658 of band 3. Erythrocytes that are Hill-
positive and Dantu-positive carry a hybrid sialoglycoprotein 
containing part of the GPA and GPB amino acid sequence and 
are also Wr(b–).17
Owing to the rarity of the Wr(b–) phenotype, data on 
the clinical significance of anti-Wrb are scanty. One alloanti-
Wrb, in a Wr(a–b–), GPA-variant individual, was evaluated 
by chemiluminescence assay, and the findings suggested 
the antibody was likely to cause destruction of incompatible 
RBCs.18 Many examples of autoanti-Wrb have been reported. 
Some examples of the autoantibody have been clinically 
significant and others benign.
Wda (DI5)
The Wda antigen was reported in two large nuclear 
Hutterite families. In 1981, Lewis and Kaita first reported 
the antibody defining the Wda antigen.19 Wda is destroyed by 
α-chymotrypsin.20 Wda is the result of a single point mutation 
that causes the amino acid change Val557Met.
Anti-Wda can be found in sera containing other low-
prevalence antigens. The antibody often reacts as a saline 
agglutinin. Only one IgG example has been reported. No cases 
of HTR or HDFN have been reported.
Rba (DI6)
The Rba antigen was described by Contreras in 1978.21 Rba 
is destroyed by α-chymotrypsin.22 Rba is the result of a single 
point mutation that causes the amino acid change Pro548Leu.
The antibody can be found in sera containing antibodies 
to other low-prevalence antigens and often reacts as a saline 
agglutinin. Only one IgG example of anti-Rba has been 
reported. No cases of HTR or HDFN have been reported.
WARR (DI7)
Coghlan et al. reported a case in 1991 of mild HDFN 
caused by an antibody to a low-prevalence antigen that they 
named WARR.23 The antigen is very rare and has been found 
in two related kindreds. The antigen was detected in the oldest 
member of the kindred, an absentee Shawnee. It is believed 
that the antigen may be unique to Native American individuals. 
Issitt and Anstee reported that even though the antigen is 
rare, the antibody is not.22 WARR is the result of a single point 
mutation that causes the amino acid change Thr552Ile.
ELO (DI8)
The low-prevalence RBC antigen ELO was detected in 
1979 (unpublished observations cited by Tippett). The findings 
were published by Coghlan et al. in 1993.24 ELO was assigned 
to the DI system in 1998, when Zelinski et al. published their 
findings that established the association between ELO and 
the gene controlling Diego blood group polymorphisms.25 The 
ELO antigen (Arg432Trp) is carried in the first ectoplasmic 
loop of band 3.
HDFNs caused by anti-ELO have been reported. In 
experiments with enzyme-treated erythrocytes, Jarolim et 
al. reported that in the two anti-ELO samples they studied, 
one reacted with α-chymotrypsin and pronase-treated RBCs, 
which was an unexpected finding.26
Wu (DI9)
The Wu antigen was also called Hov and Haakestad by 
different investigators. The antigen was reported by three 
different individuals and given three different names. In 1972, 
an abstract describing Moa27 was published that mentioned a 
new low-prevalence antigen called Haakestad. Then in 1973, 
Szaloky et al.28 described an antibody they named anti-Hov, 
and in 1976, Kornstad described the Wu antigen.29 In 1987, 
Kornstad30 published data that showed that Haakestad and 
Hov were the same antigen, and in 1992, Moulds et al.31 
showed that Hov and Wu were the same antigen. Wu was 
selected as the official name. This antigen is well developed 
at birth, and it is destroyed by α-chymotrypsin and pronase.
The antigen Wu (Wulfsberg), Gly565Ala, is carried 
in the third ectoplasmic loop of band 3. There is a serologic 
relationship between Wu and two other low-prevalence 
antigens in the DI system, NFLD and Bow, which are described 
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later.32 Adsorption studies demonstrated that RBCs positive 
for either antigen will remove all three antibodies. This is 
likely to happen as these antigens are the result of amino acid 
substitutions at the same position, and cross-reactivity surely 
occurs.17 The Wu antigen is antithetical to the DISK antigen 
(DI22).
Bpa (DI10)
In 1964, Cleghorn (unpublished observations 1962–1967) 
found a serum that contained multiple antibodies to multiple 
known low-prevalence antigens and also contained a new 
specificity that he named anti-Bpa.33
The Bpa antigen is associated with the amino acid 
substitution Asn569Lys in the transmembrane domain close 
to the third extracellular loop. This area is sensitive to trypsin, 
α-chymotrypsin, pronase, and papain.4
Moa (DI11)
Kornstad and Brocteur, in 1972, described the first 
example of anti-Moa in a serum being used to screen random 
donors for the low-prevalence antigen Jna.27 Moa is the result 
of a mutation at the fourth ectoplasmic loop that changed the 
amino acid at position 656 (Arg656His). Another mutation 
at the same amino acid position gives rise to the Hga antigen 
(see next section). Moa antigens are not destroyed by trypsin, 
α-chymotrypsin, ficin, or pronase.
Hga (DI12)
Anti-Hga was reported by Rowe and Hammond in a serum 
that contained a warm reactive autoantibody along with anti-
Pta, -Wda, and -BOW.34 The fourth ectoplasmic loop carries 
the Hga (Hughes) antigen and is associated with the amino 
acid residue substitution Arg656Cys. Hga is not destroyed by 
trypsin, α-chymotrypsin, ficin, or pronase.
Vga (DI13)
Young, in 1981, reported the presence of anti-Vga in 
one serum that also contained anti-Wu.35 Anti-Vga is not 
uncommon in sera containing multiple antibodies to low-
prevalence antigens. Vga (Van Vugt), Tyr555His, is carried 
in the third ectoplasmic loop of band 3 and is destroyed by 
α-chymotrypsin and pronase.
Swa (DI14)
Anti-Swa was described by Cleghorn in 1959.36 In 1987, 
Contreras et al. reported heterogeneity among anti-Swa and 
reported the existence of a second antigen related to Swa.37 It 
was found that some Sw(a+) RBCs reacted with all examples of 
anti-Swa, but others only reacted with some of the Swa antisera. 
The difference was shown to be qualitative, not quantitative. 
The RBCs that reacted with all anti-Swa were said to contain 
two antigens, Swa and SW1. The RBCs that only reacted with 
some of the anti-Swa were said to be Sw(a+) but negative for 
SW1. Family studies confirmed the theory that the difference 
between the two antigens is a qualitative one.38 In addition, 
a serologic relationship between Swa, SW1, and the low-
prevalence antigen Fra has also been reported.37
Two mutations in exon 16 have been associated with 
the Swa antigen, 1937G>A, which changes Arg646Gln, and 
1936C>T, which causes the Arg646Trp change.
BOW (DI15)
Anti-BOW was first described by Chaves et al. in 1988.39 
The antibody caused an unexplained incompatible crossmatch. 
BOW is the result of a single point mutation that causes the 
amino acid change Pro561Ser, and it is carried in the third 
ectoplasmic loop of band 3. The antigen is destroyed by 
pronase and α-chymotrypsin. The BOW antigen is antithetical 
to the NFLD antigen.
NFLD (DI16)
Lewis et al., in 1984, described a new low-prevalence 
antigen, NFLD, in a white family of French extraction.40 In 
1988, Okubo et al. described the presence of the NFLD antigen 
in the Japanese population.41 It is interesting to mention that 
tests with NFLD+ RBCs in Japan detected 67 examples of anti-
NFLD, and most of these examples were single antibodies.
NFLD is associated with the amino acid residue 
substitution Pro561Ala as the result of the single nucleotide 
change 1681C>G. As expression of the BOW antigen is also the 
result of a substitution at amino acid residue 561 (Pro561Ser), 
NFLD and BOW can be considered to be antithetical antigens. 
Expression of NFLD is also associated with a second mutation, 
1287A>T, which causes the amino acid change, Glu429Asp. 
This suggests that the NFLD epitope may be formed through 
an association or interaction between the first (residue 429) 
and third (residue 561) extracellular loops of band 3.
Jna (DI17)
Kornstad et al. reported a new antibody, anti-Jna, in a 
serum containing anti-Wra and anti-Bpa.41 They presented 
studies of three unrelated individuals with Jn(a+) RBCs. Two 
of them presented with nucleotide substitutions of Pro556Ser. 
The third individual showed a change that predicted Pro556Ala 
and was later shown to define the KREP antigen (see next 
section). These changes were recognized at the serologic level 
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before the polymorphisms were established by Poole et al. in 
1997.43
KREP (DI18)
Found in 1997 during investigation of the second Jn(a+) 
proband, KREP was named after the antigen-positive donor 
and assigned to the Diego blood group system in 1998. This 
antigen is the result of an SNP at 1696C>G, which causes the 
amino acid change Pro556Ala. As expression of both Jna and 
KREP antigens is the result of substitutions of Pro556, they 
can be considered antithetical antigens.43
Tra (DI19)
Cleghorn found anti-Tra in 12 of 18 sera that also contained 
anti-Wra.33 This antigen has been called Lanthois in some 
publications. Tra is the result of a single point mutation that 
causes the amino acid change Lys551Asn.
Fra (DI20)
The Fra antigen has been reported in three Mennonite 
kindreds in Manitoba, Canada. A point mutation in exon 13 
of SLC4A1 accounts for a Glu480Lys substitution in band 3, 
which controls Fra antigen expression.44 Based on these results 
Fra was assigned to the Diego blood group system. Fra seems 
to be related to Swa. Both Sw(a+) SW:1 and Sw(a+) SW:–1 will 
adsorb anti-Swa and anti-Fra, but Fr(a+) RBCs will adsorb 
anti-Fra but not anti-Swa.45
SW1 (DI21)
SW1 was documented in 1987, after being revealed by 
heterogeneity among sera containing anti-Swa. It was assigned 
to the Diego blood group system in 2000.46 The SW1 antigen 
is linked to a mutation in exon 16 (1936C>T), which causes 
the Arg646Trp amino acid change. Refer to the Swa review in 
a previous section.
DISK (DI22)
A high-prevalence antigen antithetical to DI9 (Wu) 
has been identified.47 The new antigen, DI22 (DISK), was 
characterized by an apparently naturally occurring, strongly 
agglutinating antibody reactive at both 18°C and 37°C and by 
the indirect antiglobulin test. DISK was shown to be sensitive 
to α-chymotrypsin treatment, but resistant to other commonly 
used proteases. Targeted sequence analysis of SLC4A1 exon 
14 revealed homozygosity in the proband and heterozygosity 
in a sample from her brother for the mutation 1694G>C that 
encodes Gly565Ala. The RBCs of her brother reacted more 
weakly with her antibody, suggesting that the anti-DISK 
exhibits dosage in DI:9, 22 individuals.
Poole et al. suggest that anti-DISK may be of clinical 
significance based on its serologic characteristics even though 
it could not be confirmed at the time.47
The Diego Null Phenotype
In 1983, Biro et al.48 described a healthy Mexican blood 
donor initially thought to be Di(a–b–), but further testing 
showed the donor’s RBCs were Di(a–b+w). The donor’s RBCs 
were tested with eight samples of anti-Dib and failed to react 
with two of them, but it was shown that the donor’s RBCs 
will adsorb and elute the anti-Dib present in the two antisera 
that were macroscopically nonreactive. Other reports have 
mentioned the weakened reactivity of the Dib antigens of some 
individuals.48–50
In 2000, Ribeiro and colleagues reported the case of a child 
with severe hereditary spherocytosis caused by the absence of 
band 3.51 Defects in SLC4A1 are the cause of spherocytosis 
type 4. Spherocytosis is a hematologic disorder characterized 
by numerous abnormally shaped erythrocytes, which are 
spheroidal and may cause chronic hemolytic anemia. The 
absence of band 3 suggests that the patient represents the 
Di(a–b–) phenotype.
Contrary to initial belief, homozygosity for mutations in 
SLC4A1 (lack of band 3) is not incompatible with life. That 
the lack of band 3 is not incompatible with life has been 
demonstrated in experimental evidence using engineered 
knockout mice and naturally occurring knockouts in Japanese 
black cattle, and it also has been reported in humans.3,52,53
In the article, Ribeiro et al.51 indicated that the child 
probably survived because the family history was known, 
including the underlying mutation that caused band 3 and 
protein 4.2 to be absent. At the time, the prognosis of the 
child was uncertain; she was transfusion dependent and 
also sustained by oral doses of bicarbonate to counteract the 
renal acidosis that resulted from the absence of band 3 in her 
kidneys.
Summary
For 40 years (1955–1995), Dia and Dib were the Diego 
system. In 1995, Wra and Wrb were assigned to the system. 
Since then, a combination of serologic knowledge with 
discoveries from biochemical and molecular research has 
allowed another 18 antigens to be assigned to the system; all 
but one are of low prevalence.
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There is scanty or no data on the clinical significance of 
most of the antibodies in the Diego system. Anti-Dia, -Wra, 
-ELO, -BOW, -Swa, -Fra, and -SW1 have been associated with 
HDFN, and anti-Wra has also been associated with HTR. 
Antibodies against the high-prevalence antigen Dib have been 
associated with mild HTR.
The antibodies directed against low-prevalence antigens 
in the Diego system are produced with no obvious immunizing 
stimulus. Antibodies to all low-prevalence antigens are almost 
invariably found in antisera that contain multiple antibodies 
to low-prevalence antigens. In contrast, anti-Dia is usually 
found as a single specificity and only occasionally does it occur 
in plasma containing multiple antibodies to low-prevalence 
antigens.
Mutations in the SLC4A1 gene that encodes the Di system 
antigens can result in various defects, some of which are 
critical to the organism, such as hereditary spherocytosis or 
renal tubule acidosis. Other mutations seem to be benign, 
producing changes that result in new antigens.
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